AMINOLOGICS Co. Ltd

As of March 31, 2026, AMINOLOGICS Co. Ltd carries a market capitalization of 119.80B, placing it among publicly traded companies globally. Its enterprise value stands at 68.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

AMINOLOGICS Co. Ltd's next confirmed earnings release is scheduled for November 18, 2026.

As of March 31, 2026, AMINOLOGICS Co. Ltd has 87.83M shares outstanding.

As of March 31, 2026, AMINOLOGICS Co. Ltd trades at a trailing price-to-earnings ratio of 53.03. The price-to-sales ratio is 5.28, and the price-to-book ratio stands at 2.10.

As of March 31, 2026, AMINOLOGICS Co. Ltd trades at an EV/EBITDA multiple of 16.28 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.40 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. AMINOLOGICS Co. Ltd trades at an EV/FCF ratio of 7.57, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 68.31B versus a market cap of 119.80B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, AMINOLOGICS Co. Ltd maintains a current ratio of 2.75, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.13, indicating elevated leverage, while an interest coverage ratio of 2.88 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, AMINOLOGICS Co. Ltd posted a return on equity (ROE) of 4.05, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.56 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.08, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.66, useful for judging operating efficiency across full business cycles. The company generates approximately 574.07M in revenue per employee across its workforce of 39.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.30 indicates how many times AMINOLOGICS Co. Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, AMINOLOGICS Co. Ltd recorded 60.53M in income tax expense. That works out to an effective tax rate of 2.61, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.32B, leaving 2.26B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, AMINOLOGICS Co. Ltd's stock has gained approximately 1.96% over the past 52 weeks. The 50-day moving average sits at 1,085.42, while the 200-day moving average is 1,276.16.

Over the twelve months ended March 31, 2026, AMINOLOGICS Co. Ltd generated 22.68B in revenue and converted that into 2.26B in net income, yielding earnings per share of 25.72. EBITDA reached 4.20B, while operating income came in at 3.71B.

As of March 31, 2026, AMINOLOGICS Co. Ltd holds 68.13B in cash and equivalents against 16.64B in total debt, resulting in a net debt position of -15.55B. Total book value stands at 57.11B, with working capital of 52.30B providing operational flexibility.

AMINOLOGICS Co. Ltd produced 7.63B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -30.00M in capital expenditures, free cash flow totaled 7.60B - equivalent to 86.51 per share.

Over the twelve months ended March 31, 2026, AMINOLOGICS Co. Ltd posted a gross margin of 45.13, reflecting its pricing power and cost economics. The operating margin of 16.37 and net profit margin of 9.96 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 6.34, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -16.45, meaning AMINOLOGICS Co. Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

AMINOLOGICS Co. Ltd's most recent stock split took place on May 4, 2011 with a 732:797 split ratio.

As of March 31, 2026, AMINOLOGICS Co. Ltd has an Altman Z-Score of 2.37, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.